# US 2017/0370943 A1 · Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0370943 A1
- Document ID: US20170370943A1
- Status: Published application
- Kind: A1
- Application number: 15/636,076
- Filed: 2017-06-28
- Published: 2017-12-28
- Earliest claimed: 2012-03-13
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: JENNIFER E. VAN EYK; ALLEN DALE EVERETT; ZHICHENG JIN
- Web page: https://patentgrep.com/patent/US20170370943A1

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- G01N 33/6842: {Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
- H01J 49/0027: {Methods for using particle spectrometers}
- H01J 49/0077: {specific reactions other than fragmentation}
- G01N 2440/18: citrullination
- G01N 2800/28: Neurological disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- H01J: ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS (spark-gaps H01T; electric arc lamps H05B31/00; particle accelerators H05H)

## Abstract

The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injury or neurodegeneration. In one embodiment, a method for diagnosing brain injury in a patient comprises the steps of (a) obtaining a sample from the patient; (b) determining the ratio of citrullinated to unmodified arginine residues at one or more arginine residues of one or more brain injury biomarker proteins; and (c) correlating the ratio to a patient having brain injury or to a patient not having brain injury, thereby providing the diagnosis.

## Claims

### Claim at position 1

1-60. (canceled)

### Claim 61

A method for detecting citrullinated brain injury biomarker proteins in a sample from a subject, the method comprising:
detecting in a subject's sample citrullinated arginine residues in citrullinated brain injury biomarker protein glial fibrillary acidic protein (GFAP) and/or citrullinated brain injury biomarker protein myelin basic protein (MBP) by contacting the citrullinated arginine residues in the citrullinated brain injury biomarker proteins with an antibody that specifically binds to said citrullinated arginine residues or by detecting the citrullinated arginine residues using mass spectrometry; thereby detecting citrullinated brain injury biomarker proteins in the subject's sample.

### Claim 62 (depends on 61)

The method of claim 61, wherein the citrullinated GFAP is citrullinated at one or more arginine (R) amino acid residues selected from R88, R105, R124, R126, R136, R173, R217, R258, R270, R286, R287, R367, and R406, and the citrullinated MBP is citrullinated at one or more arginine (R) amino acid residues selected from R31, R43, R49, R65, R107, R113, R162, and R169.

### Claim 63 (depends on 61)

The method of claim 61, further comprising detecting citrullinated brain injury biomarker protein neurogranin (NRGN).

### Claim 64 (depends on 63)

The method of claim 63, wherein the citrullinated NRGN is citrullinated at one or more arginine (R) amino acid residues selected from R38, R43, R51, R53, and R68.

### Claim 65 (depends on 61)

The method of claim 61, further comprising detecting in the subject's sample one or more citrullinated brain injury biomarker proteins selected from the group consisting of citrullinated tubulin beta-4B chain, tubulin alpha-1B chain, CNPase, PPIA, Septin-7, Elongation factorl-alpha2, TPPP, TPPP3, Ermin Isoform 2, NDRG2 Isoform 2, astrotactin 1 (ASTN1), brain angiogenesis inhibitor 3 (BAI3), carnosine dipeptidase 1 (CNDP1), ERMIN, glutamate receptor metabotropic 3 (GRM3), kelch-like protein 32 (KLH32), melanoma antigen family E,2 (MAGE2), neuregulin 3 (NRG3), oligodendrocyte myelin glycoprotein (OMG), solute carrier family 39 (zinc transporter), reticulon 1 (RTN1), MT3, and peptidylarginine deiminase types 1-4 and 6 (PAD1-4 and PAD6).

### Claim 66 (depends on 61)

The method of claim 61, wherein the subject's sample is selected from the group consisting of blood, peripheral blood, serum, plasma, cerebrospinal fluid (CSF), urine, saliva, stool and synovial fluid.

### Claim 67 (depends on 61)

The method of claim 61, wherein the detecting of antibody binding is accomplished using an immunoassay, and wherein the detecting by mass spectrometry is accomplished using multiple reaction monitoring mass spectrometry (MRM-MS).

### Claim 68 (depends on 61)

The method of claim 61, wherein the subject has or is suspected of having a brain injury or a neurodegenerative disease.

### Claim 69 (depends on 68)

The method of claim 68, wherein the neurodegenerative disease is selected from hemorrhagic stroke, ischemic stroke, chronic traumatic encephalopathy, Alzheimer's disease, multiple sclerosis, or Parkinson's Disease.

### Claim 70

A method for detecting autoantibodies against a citrullinated brain injury biomarker protein in a sample from a subject, the method comprising the steps of:
(a) contacting a biological sample obtained from the subject with citrullinated brain injury biomarker protein glial fibrillary acidic protein (GFAP) and/or citrullinated brain injury biomarker protein myelin basic protein (MBP); and
(b) detecting the binding of the citrullinated GFAP and/or citrullinated MBP brain injury biomarker proteins to autoantibodies in the sample which are specific for the citrullinated brain injury biomarker proteins, said detection of binding being indicative of the presence of citrullinated brain injury biomarker protein autoantibodies.

### Claim 71 (depends on 70)

The method of claim 70, wherein the citrullinated GFAP is citrullinated at one or more arginine (R) amino acid residues selected from R88, R105, R124, R126, R136, R173, R217, R258, R270, R286, R287, R367, and R406, and the citrullinated MBP is citrullinated at one or more arginine (R) amino acid residues selected from R31, R43, R49, R65, R107, R113, R162, and R169.

### Claim 72 (depends on 70)

The method of claim 70, further comprising contacting the sample with one or more citrullinated brain injury biomarker proteins selected from the group consisting of tubulin beta-4B chain, tubulin alpha-1B chain, CNPase, PPIA, Septin-7, Elongation factorl-alpha2, TPPP, TPPP3, Ermin Isoform 2, NDRG2 Isoform 2, astrotactin 1 (ASTN1), brain angiogenesis inhibitor 3 (BAI3); carnosine dipeptidase 1 (CNDP1); ERMIN; glutamate receptor metabotropic 3 (GRM3); kelch-like protein 32 (KLH32); melanoma antigen family E,2 (MAGE2); neuregulin 3 (NRG3); oligodendrocyte myelin glycoprotein (OMG); solute carrier family 39 (zinc transporter); reticulon 1 (RTN1); MT3, and peptidylarginine deiminase, types 1-4 and 6 (PAD1-4 or PAD6)

### Claim 73 (depends on 70)

The method of claim 70, wherein the binding is detected by immunosorbent assay, by immunoprecipitation, or by immunoblotting.

### Claim 74 (depends on 70)

The method of claim 70, further comprising contacting the biological sample obtained from the subject with citrullinated brain injury biomarker protein neurogranin (NRGN).

### Claim 75 (depends on 74)

The method of claim 74, wherein citrullinated NRGN is citrullinated at one or more arginine (R) amino acid residues selected from R38, R43, R51, R53, or R68.

### Claim 76 (depends on 70)

The method of claim 70, wherein the biological sample is blood, serum, plasma, cerebrospinal fluid (CSF), urine, saliva, stool and synovial fluid.

### Claim 77

A method of detecting efficacy of treatment in a subject who is being treated for brain injury, the method comprising:
a. measuring at a first time point the level of autoantibodies to at least two citrullinated brain injury biomarker proteins selected from the group consisting of neurogranin (cit-NRGN), glial fibrillary acidic protein (cit-GFAP), and/or citrullinated myelin basic protein (cit-MBP), in a sample obtained from the subject prior to initiating brain injury treatment in the subject;
b. measuring the levels of autoantibodies to cit-NRGN, cit-GFAP and/or cit-MBP biomarker proteins using a cit-NRGN-specific peptide, a cit-GFAP-specific peptide and/or a cit-MBP-specific peptide that specifically binds the autoantibodies in a sample obtained from the subject at one or more time points after initiating brain injury treatment in the subject; and
c. detecting that the subject's brain injury treatment is efficacious if the measured levels of autoantibodies that bind to the cit-NRGN, cit-GFAP and/or cit-MBP peptide in step (b) are decreased relative to the levels of autoantibodies to cit-NRGN, cit-GFAP and/or cit-MBP measured at the first time point in step (a).

### Claim 78 (depends on 77)

The method of claim 77, wherein the cit-NRGN is citrullinated at one or more arginine (R) amino acid residues selected from R38, R43, R51, R53, or R68; the cit-GFAP is citrullinated at one or more arginine (R) amino acid residues selected from R88, R105, R124, R126, R136, R173, R217, R258, R270, R286, R287, R367, and R406; and the cit-MBP is citrullinated at one or more arginine (R) amino acid residues selected from R31, R43, R49, R65, R107, R113, R162, and R169.

### Claim 79 (depends on 77)

The method of claim 77, further comprising contacting the sample with one or more citrullinated brain injury biomarker proteins selected from the group consisting of tubulin beta-4B chain, tubulin alpha-1B chain, CNPase, PPIA, Septin-7, Elongation factorl-alpha2, TPPP, TPPP3, Ermin Isoform 2, NDRG2 Isoform 2, astrotactin 1 (ASTN1), brain angiogenesis inhibitor 3 (BAI3); carnosine dipeptidase 1 (CNDP1); ERMIN; glutamate receptor metabotropic 3 (GRM3); kelch-like protein 32 (KLH32); melanoma antigen family E,2 (MAGE2); neuregulin 3 (NRG3); oligodendrocyte myelin glycoprotein (OMG); solute carrier family 39 (zinc transporter); reticulon 1 (RTN1); MT3, and peptidylarginine deiminase, types 1-4 and 6 (PAD1-4 or PAD6).

### Claim 80 (depends on 77)

The method of claim 77, wherein the sample is blood, serum, plasma, cerebrospinal fluid (CSF), urine, saliva, stool and synovial fluid.
